Drug intelligence / Profile preview

BXP-154

Development stage: Phase 2
Lead developer: Bio 54
Modality: Small Molecules
Administration: Topical

Overview

BXP-154 is a small molecule drug developed by Bio 54 LLC for the treatment of external bleeding, specifically targeting hemorrhage in patients on anticoagulant therapy. It is formulated as a topical agent intended for self-administration to stop bleeding from minor wounds, such as those resulting from punch biopsies. The drug has completed Phase 2 clinical trials evaluating its efficacy and safety in reducing time to hemostasis and preventing re-bleeding in anticoagulated patients. Its precise mechanism of action has not been publicly disclosed[1][2][5].

Other names: BXP154BXP-154BXP 154

Beyond the preview

Go deeper on BXP-154.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BXP-154.

Explore the full profile